katekins 的抗糖尿病作用通过多个受体进行介导,这种机制通过分子对接和动态模拟得出结论
Muhanad Salih1, Mosab Yahya Alnour2, Tarig Omer Ahmed3
1Department of Pharmacology, Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan.
Journal of biomolecular structure & dynamics
|May 6, 2025
概括
这项研究揭示了catechins作为-葡萄糖载体-2的潜在抑制剂和葡萄糖类-1受体-1的激动剂,为抗糖尿病药物发现提供了新的见解.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 糖尿病是一种严重的全球健康挑战,具有严重的长期并发症.
- 目前的糖尿病治疗有局限性,需要新的治疗策略和药物发现.
- katekins,天然的黄类化合物,显示抗糖尿病的潜力,但它们的分子机制尚未完全理解.
研究的目的:
- 阐明基因素降血糖作用背后的分子机制.
- 为了研究catechins与参与葡萄糖调节的关键点的相互作用.
主要方法:
- 用分子对接选来评估甲基素结合亲缘关系.
- 进行了分子动力学模拟,以分析与标蛋白的甲基素相互作用.
- 关键目标包括葡萄糖类-1受体-1,胰腺ATP敏感通道,二基酸酶-4,和-葡萄糖转运体-2.
主要成果:
- 所有测试的甲基因都显示出作为-葡萄糖转运体-2抑制剂的潜力,这是一个新的发现.
- катехин还表现出作为具有不同亲和力的葡萄糖类-1受体-1激动剂的活性.
- (-) - 乙甲基3-O-酸盐和 (-) - 甲基3-O-酸盐被确定为对ATP敏感通道和二基酸酶-4的强有力的抑制剂.
结论:
- 甲基素表现出多方面的抗糖尿病机制,包括新的-葡萄糖转运体-2-2的抑制.
- (-) 甲基3-O-酸盐和 (-) 甲基3-O-酸盐是进一步临床前和临床开发的有希望的候选物.
- 这些发现为开发基于catechin的抗糖尿病疗法开辟了新的途径.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1000
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1000
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K


